<DOC>
	<DOCNO>NCT02928432</DOCNO>
	<brief_summary>Abiraterone acetate ( AA ) show favourable impact overall survival , administer prednisone decrease adverse event relate CYP171A suppression . Our hypothesis change prednisone dexamethasone CRPC patient progress biochemically AA + prednisone improve number length response , also improve tolerance treatment , decrease adverse event associate moderate dosage steroid use chronically .</brief_summary>
	<brief_title>SWITCH : Study Prednisone Dexamethasone Change mCRPC Patients Treated With Abiraterone</brief_title>
	<detailed_description>This phase II multicentric-study analyse role steroid switch patient receive AA . Previous retrospective data ( Lorente et al , BJC 2014 ) show change prednisone dexamethasone CRPC patient treat AA post-docetaxel lead durable biochemical response 40 % case . Recently , superiority dexamethasone prednisone PSA response report phase II trial include 82 chemotherapy-naive metastatic CRPC patient . In study patient biochemical and/or limited radiological progression AA + prednisone prospectively enrol . The principal objective evaluate percentage PSA responses clinically stable metastatic CRPC patient least 12 week AA + prednisone . Secondary aim include time biochemical progression , time first radiological progression , overall survival evaluation safety profile . Biochemical response monitor PSA determination every 4 week , define ≥ 30 % decline PSA baseline , confirm second reading . PSA progression evaluate accord PCWG2 criterion . Radiological response re-evaluated every 12-16 week use bone CT-scan accord RECIST v1.1 PCWG2 criterion . Translational study : archival tissue obtain patient , perform PTEN TMPRSS-ERG rearrangement evaluation . Plasma collect AA + prednisone progression study androgen receptor status plasma .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Provision sign informed consent 2 . Patients must 18 year old old 3 . Patients must acceptable performance status study entry ECOG &lt; 2 , without prior deterioration due disease clinical progression abiraterone plus prednisone 4 . Patients must prior histological confirmation prostate cancer diagnosis prior study entry 5 . Maintained castration status LHRH analogs/antagonist surgical castration Testosterone blood level &lt; 0.5ng/mL documented initiation prior abiraterone plus prednisone treatment confirm study entry . Patients LHRHa must able continue duration study . 6 . Biochemical progression abiraterone plus prednisone require study entry . This progression document rise PSA value increase ≥25 % &gt; 2ng/dL nadir , must confirm second determination least 2 week later document study entry . 7 . Candidates must able swallow pill continue abiraterone acetate dose 1000mg/24h must contraindication dexamethasone use 0.5 mg/24h . 8 . Patients must asymptomatic symptomatic deterioration attributable prostate cancer progression study entry 9 . Absence significant radiological progression abiraterone plus prednisone study entry . Only case limit progression eligible : ) develop new visceral , nodal soft tissue metastasis ; b ) measurable target lesion abiraterone plus prednisone accord RECIST 1.1 increase 40 % baseline best response treatment measurement ; c ) must &lt; 3 new bone metastasis bonescan baseline accord PCWG2 10 . Acceptable hematological , hepatic renal function , without contraindication administration abiraterone : ) WBC count &gt; 2000/mm^3 ; b ) Haemoglobin level &gt; 10 g/dL ; c ) Platelets &gt; 75000/mm^3 ; AST/ALT &lt; 2.5 time upper normal limit ; Total bilirubin &lt; 1.5 time upper normal limit ; Creatinine value &lt; 1.5 time upper normal limit creatinine clearance &gt; 50 ml/min EXCLUSION CRITERIA 1 . Any medical contraindication continue abiraterone acetate receive continuous daily lowdose dexamethasone ( 0.5 mg/24h ) 2 . Any event consider clinical progression abiraterone acetate attend physician investigator team . 3 . Any skeletal symptomatic event related prostate cancer progression abirateroneacetate , except administration external beam radiotherapy due bonemetastasis relatedpain single area result adequate symptom control least 4weeks study entry . 4 . Radiological progression : ) New nodal , visceral soft tissue metastasis treatment Abiraterone acetate prednisone ; b ) increase target lesion &gt; 40 % accord RECIST v1.1 criterion ; c ) know visceral , nodal soft tissue metastasis localisation cause symptomatic progression , ) ≥ 3 new bone metastasis bonescan treatment abiraterone plus prednisone . 5 . Previous cancer diagnosis , except patient localize malignant tumour five year cancerfree , well subject history skin cancer ( nonmelanoma type ) excise situ carcinoma . 6 . Any prior medical history , psychiatric character , , accord judgement investigator , might interfere subject 's granting informed consent safe execution procedure require study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Castration-Resistant Prostate Cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Steroids Switch</keyword>
</DOC>